Abstract: . . .  exercise and diet therapy; oral antihyperglycemic agents or, when necessary, insulin are utilized for additional support. Just as in the individual with Type 1 diabetes , the Type 2 individual on these drugs will need to work with their physician in adjusting the dosage of any med- ications. The difference however, is the goal in Type 2 diabetes is to achieve satisfactory blood sugar control without the aid of drugs. In fact, in most cases of Type 2 diabetes there can be a com- plete reversal of the disease. For professional use only not for public distribution CODE 3525 *These statements have not been evaluated by the Food and Drug Administration.This product is not intended to diagnose, treat, cure or prevent any disease. References 1. Vuksan V, Jenkins DJ, Spadafora P, et al. Konjac-mannan (glucomannan) improves glycemia and other associated risk factors for coronary heart disease in Type 2 diabetes .A randomized controlled metabolic trial. Diabetes Care 1999;22:913-9. 2. Vuksan V, Sievenpiper JL, Owen R, et al. Beneficial effects of viscous dietary fiber from Konjac-mannan in subjects with the insulin resistance syndrome: results of a controlled . . .
. . .  et al.Antidiabetic and adaptogenic properties of Momordica charantia extract.An experimental and clinical evaluation. Phytotherapy Res 1993; 7: 285–289. 5. Reljanovic M, Reichel G, Rett K, et al.Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II).Alpha Lipoic Acid in Diabetic Neuropathy. Free Radic Res 1999;31:171-9. 6. Jacob S, Ruus P, Hermann R,Tritschler HJ, et al. Oral administration of RAC-alpha-lipoic acid modulates insulin sensitivity in patients with Type-2 diabetes mellitus: a placebo-controlled pilot trial. Free Radic Biol Med 1999;27:309-14.  . . .
--2555,2,639,2173,12773